Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 1142742

Next Previous
X
Search
Drug Profile

AV 1142742

Alternative Names: AV1142742; RhuDex

Latest Information Update: 23 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Dr Falk Pharma; MediGene Ltd
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action B cell inhibitors; CD80 antigen inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary biliary cirrhosis
  • Discontinued Asthma; Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 05 Jun 2024 Dr Falk Pharma terminated the phase II trial for Primary biliary cirrhosis in Hungary, Slovakia, Italy, Poland, Belgium, Netherlands, United Kingdom and Germany
  • 05 Jun 2024 Efficacy and adverse events data from a phase IIa trial in Primary biliary cirrhosis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 29 Nov 2022 Phase-II development is still ongoing for Primary biliary cirrhosis in Hungary, Slovakia, Italy, Poland, Belgium, Netherlands, United Kingdom and Germany (EudraCT2020-001961-34)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top